{"id":"chs-1420","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking the CD47 'don't eat me' signal on cancer cells while activating CD40 on dendritic cells and macrophages, CHS-1420 promotes both innate immune activation and adaptive T-cell responses against tumors. This dual engagement aims to overcome tumor immune evasion and drive durable anti-cancer immunity.","oneSentence":"CHS-1420 is a bispecific antibody that simultaneously engages CD47 on tumor cells and CD40 on antigen-presenting cells to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:49.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07147257","phase":"PHASE1","title":"A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions","status":"COMPLETED","sponsor":"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.","startDate":"2025-02-12","conditions":"Healthy Participants","enrollment":238},{"nctId":"NCT02489227","phase":"PHASE3","title":"Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2015-08","conditions":"Plaque Psoriasis","enrollment":545}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CHS-1420","genericName":"CHS-1420","companyName":"Coherus Oncology, Inc.","companyId":"coherus-oncology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHS-1420 is a bispecific antibody that simultaneously engages CD47 on tumor cells and CD40 on antigen-presenting cells to enhance anti-tumor immunity. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}